Cardiol Therapeutics Inc.(CRDL)Earnings, Financials & Key Ratios
CRDL•NASDAQ
$1.04
Price updated Jun 27, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryCannabis and cannabinoid product companies
AboutCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.Show more
- Revenue$0
- EBITDA-$34M+14.7%
- Net Income-$34M+7.8%
- EPS (Diluted)-0.39+23.5%
- ROE-158.75%-14.6%
CRDL Price & Volume
Cardiol Therapeutics Inc. (CRDL) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Cash Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial liquidity constraints
"Cardiol Therapeutics remains a high-risk, pre-revenue biotechnology firm entirely dependent on external capital to fund its MAVERIC and ARCHER clinical programs. While the company maintains a clean balance sheet with a debt-to-equity ratio of 0.00 as of 2026Q1, the persistent quarterly net losses, which reached $10.8 million in the most recent period, necessitate ongoing equity dilution. Investors should monitor the company's ability to reach critical clinical milestones before its $27.7 million cash position is exhausted by sustained R&D expenditures."
Verdict Logic
the company's persistent quarterly cash burn of up to $7.8 million and the lack of commercial revenue suggest significant dilution risk for shareholders as the firm approaches its $27.7 million cash limit.
CRDL Growth Metrics
Cardiol Therapeutics Inc. (CRDL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM21.05%
Return on Capital
10 Years-87.06%
5 Years-99.99%
3 Years-126.23%
Last Year-160.29%
CRDL Recent Earnings
Cardiol Therapeutics Inc. (CRDL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.05+43.4%
$0.09
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.09+0.0%
$0.09
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.07+36.4%
$0.11
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.07vs $0.07+0.0% | — |
| Q2 2026 | Mar 30, 2026 | $0.05vs $0.09+43.4% | — |
| Q4 2025 | Nov 13, 2025 | $0.09vs $0.09+0.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.07vs $0.11+36.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Cardiol Therapeutics Inc. (CRDL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.04 | $116.35M | -3.78 | — | — | -158.75% | — | |
| $3.25 | $354.88M | -1.62 | — | — | -70.79% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $78.89 | $11.11B | -6466.39 | 23258.15% | -48.38% | -55.09% | — | |
| $0.74 | $33.17M | -0.89 | 15.84% | -49.3% | -1344.47% | — | |
| $512.65 | $11.82B | -39.89 | 432.05% | -27.32% | -50.15% | — |
Compare CRDL vs Peers
Cardiol Therapeutics Inc. (CRDL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CRDL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRDL Frequently Asked Questions
Cardiol Therapeutics Inc. (CRDL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CRDL profitable?
Cardiol Therapeutics Inc. (CRDL) reported a net loss of $36.4M for fiscal year 2025.
Dividend & Returns
What is CRDL's return on equity?
Cardiol Therapeutics Inc. (CRDL) has a return on equity (ROE) of -158.8%. Negative ROE indicates the company is unprofitable.
What is Cardiol Therapeutics Inc.'s free cash flow?
Cardiol Therapeutics Inc. (CRDL) had negative free cash flow of $24.3M in fiscal year 2025, likely due to heavy capital investments.